Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice
Open Access
- 23 June 2021
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 8 (2), 34-42
- https://doi.org/10.17709/2410-1893-2021-8-2-3
Abstract
Purpose of the study. There is the generalized analysis of administration of vinflunine in real clinical practice in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological). Materials and methods. This analysis gathered 27 patients with urothelial carcinoma treated using this medicine in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological). We assessed efficacy, safety profile of vinflunine in this subset of patients. Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 51,86 %, one patient demonstrated complete response. Median of response duration accounts for 3,4 months. Adverse events were observed in 28,4 %, most of them were 1-2 grades. 2 patients stopped therapy due to adverse events. Conclusion. In our analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.Keywords
This publication has 8 references indexed in Scilit:
- Практические рекомендации по лекарственному лечению рака мочевого пузыряMalignant tumours, 2021
- Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancerUrologic Oncology, 2018
- VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and IrelandInternational Journal of Oncology, 2017
- Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE studyBMC Cancer, 2016
- Treatment of relapsed urothelial bladder cancer with vinflunineAnti-Cancer Drugs, 2016
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 GuidelinesEuropean Urology, 2013
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005